OPEN VOOR INCLUSIE
06/02/2023 - EFFORT-MICB - Phase II prospective trial to evaluate the impact of 18F-FDG-PET-CT in stratifying patients with primary muscle invasive bladder cancer and tailoring the treatment accordingly.
22/04/2022 - Neo-Checkray -Neo-adjuvant chemotherapy combined with SBRT to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab (MEDI9447) in luminal B breast cancer: a phase II randomized trial.
15/03/2022 - SABR-MESCC -Separation surgery followed by Stereotactic Ablative Body Radiotherapy versus Stereotactic Ablative Body Radiotherapy alone for spinal metastases invading the spinal canal: a randomised, non-inferiority trial (SABR-MESCC).
15/02/2022 - PRIMORDIUM -A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients Protocol
06/10/2021 -PRIMALung-studie - Profylactische cerebrale bestraling of actieve opvolging met magnetische resonantiebeeldvorming bij patiënten met kleincellige longkanker
29/09/2021 - OligoRARE -Stereotactic bodyradiotherapy in addition to standard of care tretment in patients with rare oligometastatic cancers (OligoRARE): a randomized, phase 3, open-label trial
25/03/2019 - SAVE- A Phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of andorgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomy.
GESLOTEN VOOR INCLUSIE
04/03/2019 - DOSIS RCT-SPINE SBRT- Dose intensified Image-guided fractionated Stereotactic body radiation therapy for painful spinal metastases versus conventional radiation therapy: a phase II randomised controlled trial
08/05/2019 - PEGASUS- A Phase 2, Randomized, Open-label, 3-arm Study to Assess the Efficacy and Safety of relacorilant in Combination with Nab-paclitaxel for Patients with Platinum-resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
26/01/2021 - DEBIO 1143-301- A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX).
09/2020 - ENGOT-cx11/MK3475-A18- A randomized, phase 3, double-blind study of chemoradiotherapy with or without Pembrolizumab for the treatment of high-risk, locally advanced cervical cancer
09/12/2020 - EORTC1740- Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Maintenance Durvalumab versus Durvalumab plus Radiotherapy followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer
13/12/2018 - CHEERS- CHEckpoint inhibition in combination with an immunoboost of External body Radiotherapy in Solid tumors: CHEERS-trial. Een bestralingsboost na 4 cycli immuuntherapie.
23/10/2018 - EORTC1709- A phase III trial of marizomib in combinaton with standard temozolomide-base radiochemotherapy vs standard temozolomide-base radiochemotherapy alone in patients with newly diagnosed glioblastoma.
30/03/2016 - ATLAS - 56021927PCR3003- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy